Canopy Growth Corporation
| NYSE: CGC | Healthcare / Drug Manufacturers / Canada |
| 0.5600 | +0.0004 | +0.07% | Vol 9.02M | 1Y Perf -84.54% |
| Nov 30th, 2023 16:00 DELAYED |
| BID | 0.5540 | ASK | 0.5697 | ||
| Open | 0.5599 | Previous Close | 0.5596 | ||
| Pre-Market | - | After-Market | 0.56 | ||
| - - | - -% |
| Target Price | 3.06 | Analyst Rating | Hold 3.45 | |
| Potential % | 446.43 | Finscreener Ranking | ☆ 36.41 | |
| Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ★+ 42.30 | |
| Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★ 34.93 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 4.84 | Earnings Rating | Strong Buy | |
| Market Cap | 464.29M | Earnings Date | 9th Nov 2023 | |
| Alpha | -0.05 | Standard Deviation | 0.25 | |
| Beta | 1.64 |
Today's Price Range 0.54700.5720 | 52W Range 0.34604.77 | 5 Year PE Ratio Range -109.70-8.90 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | 0.34% | ||
| 1 Month | 1.21% | ||
| 3 Months | 1.82% | ||
| 6 Months | -32.93% | ||
| 1 Year | -84.54% | ||
| 3 Years | -97.90% | ||
| 5 Years | -98.33% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -22.34 | |||
ROE last 12 Months | -107.87 | |||
ROA (5Y Avg) | -12.64 | |||
ROA last 12 Months | -63.61 | |||
ROC (5Y Avg) | -13.94 | |||
ROC last 12 Months | -65.07 | |||
Return on invested Capital Q | -6.51 | |||
Return on invested Capital Y | -10.56 | |||
Assets Turnover | 0.10 | |||
Receivables Turnover | 3.60 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.40 | ||||
| 0.96 | ||||
| 4.58 | ||||
| - | ||||
| -5.30 | ||||
| -1.37 | ||||
| 1.23 | ||||
| 2.49 | ||||
| 1.33B | ||||
| Forward PE | -3.98 | |||
| PEG | -0.01 |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 2.30 | ||||
| 2.80 | ||||
| 0.41 | ||||
| 0.91 | ||||
| -26.30 | ||||
| Leverage Ratio | 2.20 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -17.40 | ||||
| -603.30 | ||||
| -581.70 | ||||
| -338.90 | ||||
| -63.87 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 253.64M | ||||
| 0.52 | ||||
| -3.43 | ||||
| 73.33 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q01 2024 | -0.10 | -0.04 | 60.00 |
| Q04 2023 | -0.12 | -0.23 | -91.67 |
| Q03 2023 | -0.13 | -0.35 | -169.23 |
| Q02 2023 | -0.18 | -0.28 | -55.56 |
| Q01 2023 | -0.20 | -0.70 | -250.00 |
| Q04 2022 | -0.24 | -0.42 | -75.00 |
| Q03 2022 | -0.23 | -0.22 | 4.35 |
| Q02 2022 | -0.14 | -0.39 | -178.57 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 12/2023 QR | -0.05 | 16.67 | Positive |
| 3/2024 QR | -0.05 | 16.67 | Positive |
| 3/2024 FY | -0.33 | 2.94 | Positive |
| 3/2025 FY | -0.14 | 41.67 | Positive |
| Next Report Date | - |
| Estimated EPS Next Report | -0.12 |
| Estimates Count | 4 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 9.02M |
| Shares Outstanding | 829.08K |
| Shares Float | 663.27M |
| Trades Count | 10.25K |
| Dollar Volume | 5.03M |
| Avg. Volume | 28.89M |
| Avg. Weekly Volume | 13.65M |
| Avg. Monthly Volume | 20.65M |
| Avg. Quarterly Volume | 52.37M |
Canopy Growth Corporation (NYSE: CGC) stock closed at 0.56 per share at the end of the most recent trading day (a 0.07% change compared to the prior day closing price) with a volume of 9.02M shares and market capitalization of 464.29M. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 4434 people. Canopy Growth Corporation CEO is David Klein.
The one-year performance of Canopy Growth Corporation stock is -84.54%, while year-to-date (YTD) performance is -75.76%. CGC stock has a five-year performance of -98.33%. Its 52-week range is between 0.346 and 4.77, which gives CGC stock a 52-week price range ratio of 4.84%
Canopy Growth Corporation currently has a PE ratio of -0.40, a price-to-book (PB) ratio of 0.96, a price-to-sale (PS) ratio of 4.58, a price to cashflow ratio of -, a PEG ratio of -0.01, a ROA of -63.61%, a ROC of -65.07% and a ROE of -107.87%. The company’s profit margin is -63.87%, its EBITDA margin is -581.70%, and its revenue ttm is $253.64 Million , which makes it $0.52 revenue per share.
Of the last four earnings reports from Canopy Growth Corporation, there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.12 for the next earnings report. Canopy Growth Corporation’s next earnings report date is -.
The consensus rating of Wall Street analysts for Canopy Growth Corporation is Hold (3.45), with a target price of $3.06, which is +446.43% compared to the current price. The earnings rating for Canopy Growth Corporation stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Canopy Growth Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Canopy Growth Corporation has a Sell technical analysis rating based on Technical Indicators (ADX : 16.56, ATR14 : 0.06, CCI20 : -19.55, Chaikin Money Flow : -0.22, MACD : -0.02, Money Flow Index : 51.68, ROC : 7.49, RSI : 46.96, STOCH (14,3) : 61.78, STOCH RSI : 0.70, UO : 42.21, Williams %R : -38.22), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Canopy Growth Corporation in the last 12-months were:
Canopy Growth Corporation
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
CEO: David Klein
Telephone: +1 855 558-9333
Address: 1 Hershey Drive, Smiths Falls K7A 0A8, ON, CA
Number of employees: 4 434
TipRanks News for CGC
Mon, 18 Sep 2023 10:45 GMT Canopy Growth (CGC) Gets a Sell from Piper Sandler
- TipRanks. All rights reserved.Wed, 06 Sep 2023 13:40 GMT Unusually active option classes on open September 6th
- TipRanks. All rights reserved.Fri, 01 Sep 2023 13:40 GMT Unusually active option classes on open September 1st
- TipRanks. All rights reserved.
